An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 162-171

  An, Yong Jin ^a   Cho, Hye Rim ^a   Kim, Tae Min ^b   Keam, Bhumsuk ^b   Kim, Jin Wook ^b   Wen, He ^a   Park, Chul Kee ^b   Lee, Se Hoon ^b   Im, Seock Ah ^b   Kim, Jeong Eun ^b   Choi, Seung Hong ^a,c   Park, Sunghyouk ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Institute for Basic Science   (South Korea)

Author keywords

CSF; diagnosis; leptomeningeal carcinomatosis; metabolomics; metastasis

Indexed keywords

ALANINE; CITRIC ACID; CREATINE; GLUCOSE; INOSITOL; LACTIC ACID; TUMOR MARKER;

ARTICLE; BIOCHEMICAL ANALYSIS; CANCER GRADING; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROMETER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; ADENOCARCINOMA; AREA UNDER THE CURVE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; METABOLOME; MULTIVARIATE ANALYSIS; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SECONDARY;

ADENOCARCINOMA; ALANINE; AREA UNDER CURVE; CASE-CONTROL STUDIES; CITRIC ACID; CREATINE; HUMANS; INOSITOL; LACTIC ACID; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MENINGEAL CARCINOMATOSIS; METABOLOME; MULTIVARIATE ANALYSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84921692242     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28949     Document Type: Article

References (52)

1. Bruna J, Gonzalez L, Miro J, et al., Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009; 115: 381-9.
2. Gwak HS, Joo J, Kim S, et al., Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 2013; 8: 599-605.
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al., Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22: 2865-72.
4. Morris PG, Reiner AS, Szenberg OR, et al., Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012; 7: 382-5.
5. Park JH, Kim YJ, Lee JO, et al., Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012; 76: 387-92.
6. Dai H, Chen Y, Elmquist WF,. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther 2005; 315: 222-9.
7. Barlesi F, Gervais R, Lena H, et al., Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol 2011; 22: 2466-70.
8. Subira D, Serrano C, Castanon S, et al., Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neurooncology 2012; 14: 43-52.
9. Shapiro WR, Johanson CE, Boogerd W,. Treatment modalities for leptomeningeal metastases. Semin Oncol 2009; 36: S46-54.
10. Jeyapalan SA, Batchelor TT,. Diagnostic evaluation of neurologic metastases. Cancer Invest 2000; 18: 381-94.
11. Dono M, Ferro P, Benedetti L, et al., Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis. J Neurooncol 2009; 91: 295-8.
12. Eskey CJ, Ogilvy CS,. Fluoroscopy-guided lumbar puncture: decreased frequency of traumatic tap and implications for the assessment of CT-negative acute subarachnoid hemorrhage. AJNR Am J Neuroradiol 2001; 22: 571-6.
13. Cho HR, Wen H, Ryu YJ, et al., An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis. Cancer Res 2012; 72: 5179-87.
14. Suhre K, Gieger C,. Genetic variation in metabolic phenotypes: study designs and applications. Nat Rev Genet 2012; 13: 759-69.
15. Kwon HN, Kim M, Wen H, et al., Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach. Kidney Int 2011; 79: 529-37.
16. Kim K, Aronov P, Zakharkin SO, et al., Urine metabolomic analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009; 8: 558-70.
17. Brindle JT, Antti H, Holmes E, et al., Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8: 1439-44.
18. Wikoff WR, Pendyala G, Siuzdak G, et al., Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 2008; 118: 2661-9.
19. Beyoglu D, Idle JR,. The metabolomic window into hepatobiliary disease. J Hepatol 2013; 59: 842-58.
20. Wen H, Yoo SS, Kang J, et al., A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol 2010; 52: 228-33.
21. Ho JE, Larson MG, Vasan RS, et al., Metabolite profiles during oral glucose challenge. Diabetes 2013; 62: 2689-98.
22. Holmes E, Loo RL, Stamler J, et al., Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008; 453: 396-400.
23. Putluri N, Shojaie A, Vasu VT, et al., Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 2011; 71: 7376-86.
24. Rocha CM, Barros AS, Gil AM, et al., Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res 2010; 9: 319-32.
25. Clarke JL, Perez HR, Jacks LM, et al., Leptomeningeal metastases in the MRI era. Neurology 2010; 74: 1449-54.
26. Taillibert S, Laigle-Donadey F, Chodkiewicz C, et al., Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 2005; 75: 85-99.
27. Tomasi G, van den Berg F, Andersson C,. Correlation optimized warping and dynamic time warping as preprocessing methods for chromatographic data. J Chemometr 2004; 18: 231-41.
28. Xia J, Broadhurst DI, Wilson M, et al., Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013; 9: 280-99.
29. Chamberlain MC,. Leptomeningeal metastasis. Curr Opin Oncol 2010; 22: 627-35.
30. Freilich RJ, Krol G, DeAngelis LM,. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38: 51-7.
31. Straathof CS, de Bruin HG, Dippel DW, et al., The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999; 246: 810-4.
32. Chamberlain MC, Sandy AD, Press GA,. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40: 435-8.
33. Hirschhaeuser F, Sattler UG, Mueller-Klieser W,. Lactate: a metabolic key player in cancer. Cancer Res 2011; 71: 6921-5.
34. Baumann F, Leukel P, Doerfelt A, et al., Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neurooncology 2009; 11: 368-80.
35. Beckert S, Farrahi F, Aslam RS, et al., Lactate stimulates endothelial cell migration. Wound Repair Regen 2006; 14: 321-4.
36. Stern R, Shuster S, Neudecker BA, et al., Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 2002; 276: 24-31.
37. Formby B, Stern R,. Lactate-sensitive response elements in genes involved in hyaluronan catabolism. Biochem Biophys Res Commun 2003; 305: 203-8.
38. Ben-Yoseph O, Badar-Goffer RS, Morris PG, et al., Glycerol 3-phosphate and lactate as indicators of the cerebral cytoplasmic redox state in severe and mild hypoxia, respectively: a 13C- and 31P-n.m.r. study. Biochem J 1993; 291: 915-9.
39. Howe FA, Barton SJ, Cudlip SA, et al., Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223-32.
40. Israel M, Schwartz L,. The metabolic advantage of tumor cells. Mol Cancer 2011; 10: 70.
41. Kim JW, Gao P, Dang CV,. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 2007; 26: 291-8.
42. Fan TW, Lane AN, Higashi RM, et al., Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer 2009; 8: 41.
43. Nakamizo S, Sasayama T, Shinohara M, et al., GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. J Neurooncol 2013; 113: 65-74.
44. Mycielska ME, Broke-Smith TP, Palmer CP, et al., Citrate enhances in vitro metastatic behaviours of PC-3M human prostate cancer cells: status of endogenous citrate and dependence on aconitase and fatty acid synthase. Int J Biochem Cell Biol 2006; 38: 1766-77.
45. Beckonert O, Monnerjahn J, Bonk U, et al., Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed 2003; 16: 1-11.
46. Sreekumar A, Poisson LM, Rajendiran TM, et al., Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-4.
47. Howells SL, Maxwell RJ, Peet AC, et al., An investigation of tumor 1H nuclear magnetic resonance spectra by the application of chemometric techniques. Magn Reson Med 1992; 28: 214-36.
48. Carmichael PL,. Mechanisms of action of antiestrogens: relevance to clinical benefits and risks. Cancer Invest 1998; 16: 604-11.
49. Cheng LL, Chang IW, Louis DN, et al., Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 1998; 58: 1825-32.
50. Hattingen E, Raab P, Franz K, et al., Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 2008; 50: 759-67.
51. Mahon MM, Williams AD, Soutter WP, et al., 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR Biomed 2004; 17: 1-9.
52. Kinoshita Y, Yokota A,. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 1997; 10: 2-12.